Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) CEO Stanley Bergman sold 43,812 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the sale, the chief executive officer directly owned 383,803 shares in the company, valued at $31,207,021.93. This represents a 10.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Henry Schein Stock Down 1.4%
Shares of NASDAQ:HSIC opened at $80.21 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The firm has a market cap of $9.20 billion, a P/E ratio of 24.53, a P/E/G ratio of 2.41 and a beta of 0.88. The company's 50-day moving average price is $78.00 and its two-hundred day moving average price is $72.39. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $89.29.
Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on HSIC shares. Weiss Ratings reissued a "hold (c)" rating on shares of Henry Schein in a research note on Monday, December 29th. Leerink Partners lifted their target price on shares of Henry Schein from $75.00 to $87.00 and gave the stock a "market perform" rating in a report on Tuesday, February 24th. Robert W. Baird set a $100.00 target price on shares of Henry Schein and gave the company an "outperform" rating in a research report on Monday, February 23rd. Morgan Stanley raised their price target on Henry Schein from $58.00 to $61.00 and gave the stock an "underweight" rating in a research report on Wednesday, February 25th. Finally, Barrington Research set a $97.00 price objective on Henry Schein and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $85.58.
Check Out Our Latest Research Report on HSIC
Hedge Funds Weigh In On Henry Schein
A number of hedge funds and other institutional investors have recently made changes to their positions in HSIC. Ameriprise Financial Inc. increased its position in shares of Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company's stock valued at $165,594,000 after buying an additional 2,199,695 shares in the last quarter. Bank of Montreal Can grew its stake in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company's stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the period. Norges Bank acquired a new position in Henry Schein in the second quarter valued at about $89,476,000. M.D. Sass LLC bought a new stake in shares of Henry Schein in the second quarter worth about $79,201,000. Finally, Schroder Investment Management Group raised its position in shares of Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company's stock worth $114,243,000 after purchasing an additional 936,471 shares during the period. 96.62% of the stock is owned by institutional investors.
Henry Schein Company Profile
(
Get Free Report)
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
